New Delhi, May 12 (PTI) Sun Pharmaceutical Industries on Thursday said it has received final approval from the US health regulator for Mesalamine extended release capsules, used to treat bowel disease, in the American market.

The company has received approval from the US Food and Drug Administration (USFDA) for the product, a generic version of Pentasa extended release capsules (500 mg), the Mumbai-based drug major said in a statement.

Also Read | TRB Tripura PGT Recruitment 2022: Apply For 300 Posts at trb.tripura.gov.in; Check Details Here.

As per March 2022 IQVIA Health data, Pentasa had annualised sales of around USD 213 million in the US market.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)